Mortality Following Durable Left Ventricular Assist Device Implantation by Timing and Type of First Infection

Overview

Journal J Thorac Cardiovasc Surg

Specialties Cardiology & Vascular Diseases
General Surgery
Pulmonary Medicine

Date 2021 Dec 13

PMID 34895722

Citations 4

Authors

Shiwei Zhou

Guangyu Yang

Min Zhang

Michael Pienta

Carol E Chenoweth

Francis D Pagani

Keith D Aaronson

Michael D Fetters

P Paul Chandanabhumma

Lourdes Cabrera

Hechuan Hou

Preeti N Malani

Donald S Likosky

Affiliations

Soon will be listed here.

Abstract

Objective: Although infections are common after left ventricular assist device implantation, the relationship between timing and type of first infection with regard to mortality is less well understood.

Methods: The Society of Thoracic Surgeons Interagency Registry for Mechanically Assisted Circulatory Support patients receiving a primary left ventricular assist device from April 2012 to May 2017 were included. The primary exposure was defined 3 ways: any infection, timing of first infection (early: ≤90 days; intermediate: 91-180 days; late: >180 days), and type (ventricular assist device specific, ventricular assist device related, non-ventricular assist device). The association between first infection and all-cause mortality was estimated using Cox regression.

Results: The cohort included 12,957 patients at 166 centers (destination therapy: 47.4%, bridge-to-transplant: 41.2%). First infections were most often non-ventricular assist device (54.2%). Rates of first infection were highest in the early interval (10.7/100 person-months). Patients with any infection had a significantly higher adjusted hazard of death (hazard ratio, 2.63; 2.46-2.86). First infection in the intermediate interval was associated with the largest increase in adjusted hazard of death (hazard ratio, 3.26; 2.82-3.78), followed by late (hazard ratio, 3.13; 2.77-3.53) and early intervals (hazard ratio, 2.37; 2.16-2.60). Ventricular assist device-related infections were associated with the largest increase in hazard of death (hazard ratio, 3.02; 2.69-3.40), followed by ventricular assist device specific (hazard ratio, 2.92; 2.57-3.32) and non-ventricular assist device (hazard ratio, 2.42; 2.20-2.65).

Conclusions: Relative to those without infection, patients with any postimplantation infection had an increased risk of death. Ventricular assist device-related infections and infections occurring in the intermediate interval were associated with the largest increase in risk of death. After left ventricular assist device implantation, infection prevention strategies should target non-ventricular assist device infections in the first 90 days, then shift to surveillance/prevention of driveline infections after 90 days.

Citing Articles

Interplay between driveline infection, vessel wall inflammation, cerebrovascular events and mortality in patients with left ventricular assist device.

Hupe J, Worthmann H, Ravenberg K, Grosse G, Ernst J, Haverich A Sci Rep. 2023; 13(1):18552.

PMID: 37899422 PMC: 10613624. DOI: 10.1038/s41598-023-45110-6.

Hemoadsorption in LVAD Surgery: Suitable in Theory?.

Ozturk M, Popov A J Cardiovasc Dev Dis. 2023; 10(7).

PMID: 37504542 PMC: 10380647. DOI: 10.3390/jcdd10070286.

Infections following left ventricular assist device implantation and 1-year health-related quality of life.

Zhou S, Yang G, Hou H, Zhang M, Grady K, Chenoweth C J Heart Lung Transplant. 2023; 42(9):1307-1315.

PMID: 37187319 PMC: 10527882. DOI: 10.1016/j.healun.2023.05.006.

Zwitterionic coating assisted by dopamine with metal-phenolic networks loaded on titanium with improved biocompatibility and antibacterial property for artificial heart.

Meng L, Huang C, Liu X, Qu H, Wang Q Front Bioeng Biotechnol. 2023; 11:1167340.

PMID: 37139045 PMC: 10150318. DOI: 10.3389/fbioe.2023.1167340.

References

Chandanabhumma P, Fetters M, Pagani F, Malani P, Hollingsworth J, Funk R . Understanding and Addressing Variation in Health Care-Associated Infections After Durable Ventricular Assist Device Therapy: Protocol for a Mixed Methods Study. JMIR Res Protoc. 2020; 9(1):e14701. PMC: 6996720. DOI: 10.2196/14701. View

Patel C, Blue L, Cagliostro B, Bailey S, Entwistle J, John R . Left ventricular assist systems and infection-related outcomes: A comprehensive analysis of the MOMENTUM 3 trial. J Heart Lung Transplant. 2020; 39(8):774-781. DOI: 10.1016/j.healun.2020.03.002. View

Frontera J, Starling R, Cho S, Nowacki A, Uchino K, Hussain M . Risk factors, mortality, and timing of ischemic and hemorrhagic stroke with left ventricular assist devices. J Heart Lung Transplant. 2017; 36(6):673-683. DOI: 10.1016/j.healun.2016.12.010. View

Holman W, Kirklin J, Naftel D, Kormos R, Desvign-Nickens P, Camacho M . Infection after implantation of pulsatile mechanical circulatory support devices. J Thorac Cardiovasc Surg. 2010; 139(6):1632-1636.e2. DOI: 10.1016/j.jtcvs.2010.01.014. View

Gordon S, Schmitt S, Jacobs M, Smedira N, Goormastic M, Banbury M . Nosocomial bloodstream infections in patients with implantable left ventricular assist devices. Ann Thorac Surg. 2001; 72(3):725-30. DOI: 10.1016/s0003-4975(01)02888-0. View

Nienaber J, Kusne S, Riaz T, Walker R, Baddour L, Wright A . Clinical manifestations and management of left ventricular assist device-associated infections. Clin Infect Dis. 2013; 57(10):1438-48. PMC: 3805171. DOI: 10.1093/cid/cit536. View

Aslam S, Xie R, Cowger J, Kirklin J, Chu V, Schueler S . Bloodstream infections in mechanical circulatory support device recipients in the International Society of Heart and Lung Transplantation Mechanically Assisted Circulation Support Registry: Epidemiology, risk factors, and mortality. J Heart Lung Transplant. 2018; 37(8):1013-1020. DOI: 10.1016/j.healun.2018.04.006. View

Aggarwal A, Gupta A, Kumar S, Baumblatt J, Pauwaa S, Gallagher C . Are blood stream infections associated with an increased risk of hemorrhagic stroke in patients with a left ventricular assist device?. ASAIO J. 2012; 58(5):509-13. DOI: 10.1097/MAT.0b013e318260c6a6. View

Likosky D, Yang G, Zhang M, Malani P, Fetters M, Strobel R . Interhospital variability in health care-associated infections and payments after durable ventricular assist device implant among Medicare beneficiaries. J Thorac Cardiovasc Surg. 2021; 164(5):1561-1568. PMC: 10150658. DOI: 10.1016/j.jtcvs.2021.04.074. View

10.

Zierer A, Melby S, Voeller R, Guthrie T, Ewald G, Shelton K . Late-onset driveline infections: the Achilles' heel of prolonged left ventricular assist device support. Ann Thorac Surg. 2007; 84(2):515-20. DOI: 10.1016/j.athoracsur.2007.03.085. View

11.

Mehra M, Uriel N, Naka Y, Cleveland Jr J, Yuzefpolskaya M, Salerno C . A Fully Magnetically Levitated Left Ventricular Assist Device - Final Report. N Engl J Med. 2019; 380(17):1618-1627. DOI: 10.1056/NEJMoa1900486. View

12.

Hemmila M, Cain-Nielsen A, Jakubus J, Mikhail J, Dimick J . Association of Hospital Participation in a Regional Trauma Quality Improvement Collaborative With Patient Outcomes. JAMA Surg. 2018; 153(8):747-756. PMC: 6142961. DOI: 10.1001/jamasurg.2018.0985. View

13.

Trachtenberg B, Cordero-Reyes A, Aldeiri M, Alvarez P, Bhimaraj A, Ashrith G . Persistent blood stream infection in patients supported with a continuous-flow left ventricular assist device is associated with an increased risk of cerebrovascular accidents. J Card Fail. 2014; 21(2):119-25. DOI: 10.1016/j.cardfail.2014.10.019. View

14.

Gordon R, Weinberg A, Pagani F, Slaughter M, Pappas P, Naka Y . Prospective, multicenter study of ventricular assist device infections. Circulation. 2013; 127(6):691-702. PMC: 3695607. DOI: 10.1161/CIRCULATIONAHA.112.128132. View

15.

Pagani F, Aaronson K, Kormos R, Mann D, Spino C, Jeffries N . The NHLBI REVIVE-IT study: Understanding its discontinuation in the context of current left ventricular assist device therapy. J Heart Lung Transplant. 2016; 35(11):1277-1283. DOI: 10.1016/j.healun.2016.09.002. View

16.

Likosky D, Harrington S, Cabrera L, DeLucia 3rd A, Chenoweth C, Krein S . Collaborative Quality Improvement Reduces Postoperative Pneumonia After Isolated Coronary Artery Bypass Grafting Surgery. Circ Cardiovasc Qual Outcomes. 2018; 11(11):e004756. PMC: 6310019. DOI: 10.1161/CIRCOUTCOMES.118.004756. View

17.

Kirklin J, Naftel D, Stevenson L, Kormos R, Pagani F, Miller M . INTERMACS database for durable devices for circulatory support: first annual report. J Heart Lung Transplant. 2008; 27(10):1065-72. DOI: 10.1016/j.healun.2008.07.021. View

18.

Molina E, Shah P, Kiernan M, Cornwell 3rd W, Copeland H, Takeda K . The Society of Thoracic Surgeons Intermacs 2020 Annual Report. Ann Thorac Surg. 2021; 111(3):778-792. DOI: 10.1016/j.athoracsur.2020.12.038. View

19.

Hannan M, Xie R, Cowger J, Schueler S, de By T, Dipchand A . Epidemiology of infection in mechanical circulatory support: A global analysis from the ISHLT Mechanically Assisted Circulatory Support Registry. J Heart Lung Transplant. 2019; 38(4):364-373. DOI: 10.1016/j.healun.2019.01.007. View

20.

Pya Y, Maly J, Bekbossynova M, Salov R, Schueler S, Meyns B . First human use of a wireless coplanar energy transfer coupled with a continuous-flow left ventricular assist device. J Heart Lung Transplant. 2019; 38(4):339-343. DOI: 10.1016/j.healun.2019.01.1316. View